Détails du produit
Synonyms
CCL19, MIP-3 beta, MIP-3-beta, ELC, MIP3B, SCYA19, EBI1 ligand chemokine
Source
Human CCL19, Tag Free (CC9-H5215) is expressed from human 293 cells (HEK293). It contains AA Gly 22 - Ser 98 (Accession # Q99731-1).
Predicted N-terminus: Gly 22
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries no "tag".
The protein has a calculated MW of 8.8 kDa. The protein migrates as 11-12 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.1 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>95% as determined by SEC-HPLC.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE

Human CCL19, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-HPLC

The purity of Human CCL19, Tag Free (Cat. No. CC9-H5215) was greater than 95% as determined by SEC-HPLC.
Avis des utilisateurs Publier un commentaire

Introduction de fond
Progrès de frontière
- Nom anglais:
C-C motif chemokine 19
- Catégorie:
- Nombre de médicaments répertoriés:
0 Détails
- Nombre de médicaments cliniques:
1 Détails
- Étape de développement la plus élevée:
Phase 1 Clinical



















